{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:01:02Z","timestamp":1794070862247,"version":"4.8.0"},"reference-count":47,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2017,8,16]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>As in other inflammatory rheumatic diseases, the objective of psoriatic arthritis (PsA) treatment is the achievement of a defined target. Recent recommendations propose aiming for remission or low disease activity; however, a consensual definition of remission is lacking. A state of minimal disease activity (MDA) has been established and is defined by low activity assessed by tender\/swollen joint counts, tender entheseal points, Psoriasis Area and Severity Index or body surface area, patient pain and global activity visual analog scale, and functional evaluation by Health Assessment Questionnaire. Since its development, MDA has been used increasingly in studies and clinical trials. In this article, the potential use of MDA as a treatment target in PsA is reviewed. The frequencies of MDA achievement with biologic disease-modifying antirheumatic drugs are summarized based on data from registries, observational studies, and clinical trials. Predictors and the prognostic effect of attaining MDA are also evaluated.<\/jats:p>","DOI":"10.3899\/jrheum.170449","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T01:25:38Z","timestamp":1510795538000},"page":"6-13","source":"Crossref","is-referenced-by-count":107,"title":["Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature"],"prefix":"10.3899","volume":"45","author":[{"given":"Laure","family":"Gossec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Korotaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"2025062500200946000_45.1.6.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208466"},{"key":"2025062500200946000_45.1.6.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025062500200946000_45.1.6.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"2025062500200946000_45.1.6.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025062500200946000_45.1.6.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025062500200946000_45.1.6.6","unstructured":"Smolen J Sch\u00f6ls M Braun J Dougados M FitzGerald O Gladman D Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update to recommendations by an international task force. Ann Rheum Dis 2017 Jul 6 (E-pub ahead of print)."},{"key":"2025062500200946000_45.1.6.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129379"},{"key":"2025062500200946000_45.1.6.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170150"},{"key":"2025062500200946000_45.1.6.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150826"},{"key":"2025062500200946000_45.1.6.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391210"},{"key":"2025062500200946000_45.1.6.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201341"},{"key":"2025062500200946000_45.1.6.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2025062500200946000_45.1.6.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025062500200946000_45.1.6.14","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J Rheumatol"},{"key":"2025062500200946000_45.1.6.15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20155"},{"key":"2025062500200946000_45.1.6.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120970"},{"key":"2025062500200946000_45.1.6.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2025062500200946000_45.1.6.18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22576"},{"issue":"Suppl 2","key":"2025062500200946000_45.1.6.19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/annrheumdis-2016-eular.3949","article-title":"Secukinumab improves minimal disease activity response rates in patients with active psoriatic arthritis: data from the randomized phase 3 study, FUTURE 2","volume":"75","author":"Coates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025062500200946000_45.1.6.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"2025062500200946000_45.1.6.21","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000119"},{"key":"2025062500200946000_45.1.6.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-eular.665corr1"},{"key":"2025062500200946000_45.1.6.23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22500"},{"key":"2025062500200946000_45.1.6.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151101"},{"key":"2025062500200946000_45.1.6.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2025062500200946000_45.1.6.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22529"},{"key":"2025062500200946000_45.1.6.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150805"},{"issue":"Suppl 10","key":"2025062500200946000_45.1.6.28","first-page":"2870","article-title":"Predictors of early minimal disease activity in PsA patients treated with anti-TNF in a real-world registry","volume":"67","author":"Zummer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025062500200946000_45.1.6.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201972"},{"key":"2025062500200946000_45.1.6.30","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20162"},{"key":"2025062500200946000_45.1.6.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150165"},{"key":"2025062500200946000_45.1.6.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110763"},{"key":"2025062500200946000_45.1.6.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.38968"},{"issue":"Suppl 2","key":"2025062500200946000_45.1.6.34","first-page":"355","article-title":"The prediction and benefits of minimal disease activity in patients with psoriatic arthritis in the ADEPT trial","volume":"74","author":"Mease","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025062500200946000_45.1.6.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151491"},{"key":"2025062500200946000_45.1.6.36","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8595-z"},{"key":"2025062500200946000_45.1.6.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"2025062500200946000_45.1.6.38","doi-asserted-by":"publisher","DOI":"10.1186\/ar4049"},{"key":"2025062500200946000_45.1.6.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"2025062500200946000_45.1.6.40","doi-asserted-by":"publisher","DOI":"10.1186\/ar3049"},{"key":"2025062500200946000_45.1.6.41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150614"},{"key":"2025062500200946000_45.1.6.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150595"},{"key":"2025062500200946000_45.1.6.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203073"},{"key":"2025062500200946000_45.1.6.44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208806"},{"key":"2025062500200946000_45.1.6.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151296"},{"key":"2025062500200946000_45.1.6.46","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1277-1"},{"issue":"Suppl 10","key":"2025062500200946000_45.1.6.47","first-page":"1741","article-title":"Patients with active psoriatic arthritis achieving minimal disease activity with secukinumab treatment demonstrate sustained improvement of function and quality of life","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:20:29Z","timestamp":1750836029000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,1]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.3899\/jrheum.170449"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170449","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]}}}